Cellectis/$CLLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Ticker

$CLLS
Sector
Primary listing

Employees

219

Cellectis Metrics

BasicAdvanced
$327M
-
-$0.60
3.03
-

What the Analysts think about Cellectis

Analyst ratings (Buy, Hold, Sell) for Cellectis stock.

Bulls say / Bears say

Cellectis completed end-of-Phase 1 meetings with FDA and EMA for lasme-cel (UCART22) in July 2025, supporting the start of a pivotal Phase 2 trial in the second half of 2025 (GlobeNewswire)
The company held $230 million in cash, cash equivalents, and fixed-term deposits as of June 30, 2025, with funding to support clinical and manufacturing operations through the second half of 2027 (GlobeNewswire)
A strategic partnership with AstraZeneca covers three allogeneic CAR-T programs and an in vivo gene therapy project, providing non-dilutive funding and external validation of Cellectis’ platform (GlobeNewswire)
Key Phase 1 data for UCART22 and results for UCART20×22 are not anticipated until late 2025, pushing back the timeline for pivotal data that could help de-risk the stock in the near term (GlobeNewswire)
Cellectis is in arbitration with Servier regarding its CD19 license, with a tribunal decision expected by December 15, 2025; a negative decision could see Cellectis lose rights to key products and face significant compensation requirements (GlobeNewswire)
Factor Bioscience has filed a patent-infringement lawsuit in U.S. District Court, alleging Cellectis unlawfully used its mRNA/TALEN technology, which creates risks of legal costs and possible injunctions (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2025.

Cellectis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cellectis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CLLS

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs
Buy Cellectis stock | $CLLS Share Price | Lightyear